Bleomycin revisited: Towards a more representative model of IPF?

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 299, Issue 4, 2010, Pages

  Scotton, Chris J ^a   Chambers, Rachel C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BLEOMYCIN; CHEMOKINE; CYTOKINE; ENDOTHELIN; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; INTERLEUKIN 13; PROSTAGLANDIN E2; SILICON DIOXIDE; TRANSFORMING GROWTH FACTOR BETA; ACTA2 PROTEIN, MOUSE; ACTIN; ANTINEOPLASTIC ANTIBIOTIC; LUNG SURFACTANT; PROTEIN S 100; S100A4 PROTEIN, MOUSE; SCGB1A1 PROTEIN, HUMAN; SCGB1A1 PROTEIN, MOUSE; UTEROGLOBIN;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL DOG; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FIBROGENESIS; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; INFLAMMATION; INTERSTITIAL PNEUMONIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; NONHUMAN; OSMOTIC MINIPUMP; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; RADIATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED DRUG RELEASE; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; HYPERPLASIA; INTUBATION; LUNG; LUNG ALVEOLUS; METABOLISM; MOUSE; NICK END LABELING; PATHOLOGY; TOXICITY; TRANSGENIC MOUSE;

ACTINS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; DISEASE MODELS, ANIMAL; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; HYPERPLASIA; IDIOPATHIC PULMONARY FIBROSIS; IN SITU NICK-END LABELING; INTUBATION; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PULMONARY ALVEOLI; PULMONARY SURFACTANTS; S100 PROTEINS; UTEROGLOBIN;

EID: 77957373810     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00258.2010     Document Type: Editorial

References (22)

1. Adamson IY, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 77: 185-197, 1974.
2. Brown RF, Drawbaugh RB, Marrs TC. An investigation of possible models for the production of progressive pulmonary fibrosis in the rat. The effects of repeated intratracheal instillation of bleomycin. Toxicology 51: 101-110, 1988.
3. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 173: 769-776, 2006.
4. Chung MP, Monick MM, Hamzeh NY, Butler NS, Powers LS, Hunninghake GW. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am J Respir Cell Mol Biol 29: 375-380, 2003. (Pubitemid 37093996)
5. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, McMahon FB, Gleaves LA, Blackwell TS, Lawson WE. Repetitive intratracheal bleo- mycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (June 18, 2010). doi:10.1152/ajplung.00026.2010.
6. Eickelberg O, Selman M. Update in diffuse parenchymal lung disease 2009. Am J Respir Crit Care Med 181: 883-888, 2010.
7. Fleischman RW, Baker JR, Thompson GR, Schaeppi UH, Illievski VR, Cooney DA, Davis RD. Bleomycin-induced interstitial pneumonia in dogs. Thorax 26: 675-682, 1971.
8. Hodges RJ, Jenkins RG, Wheeler-Jones CP, Copeman DM, Bottoms SE, Bellingan GJ, Nanthakumar CB, Laurent GJ, Hart SL, Foster ML, McAnulty RJ. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am J Pathol 165: 1663-1676, 2004.
9. Horowitz JC, Thannickal VJ. Epithelial-mesenchymal interactions in pulmonary fibrosis. Semin Respir Crit Care Med 27: 600-612, 2006.
10. Howell DC, Johns RH, Lasky JA, Shan B, Scotton CJ, Laurent GJ, Chambers RC. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 166: 1353-1365, 2005.
11. King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, Flint A, Thurlbeck W, Cherniack RM. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164: 1025-1032, 2001.
12. Lakatos HF, Burgess HA, Thatcher TH, Redonnet MR, Hernady E, Williams JP, Sime PJ. Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation. Exp Lung Res 32: 181-199, 2006. (Pubitemid 44266711)
13. Larsson O, Diebold D, Fan D, Peterson M, Nho RS, Bitterman PB, Henke CA. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS ONE 3: e3220, 2008.
14. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 30: 835-839, 2007.
15. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40: 362-382, 2008.
16. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L152-L160, 2008.
17. Okamoto T, Amano T, Wada T, Harada M, Tanaka T. [Experimental pulmonary fibrosis induced by bleomycin]. Igaku To Seibutsugaku 80: 299-301, 1970.
18. Pinart M, Serrano-Mollar A, Llatjos R, Rocco PR, Romero PV. Single and repeated bleomycin intratracheal instillations lead to different biomechanical changes in lung tissue. Respir Physiol Neurobiol 166: 41-46, 2009.
19. Schrier DJ, Kunkel RG, Phan SH. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis 127: 63-66, 1983.
20. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132: 1311-1321, 2007. (Pubitemid 47621009)
21. Scotton CJ, Krupiczojc MA, Konigshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Maher TM, Nicholson AG, Moffatt JD, Laurent GJ, Derian CK, Eickelberg O, Chambers RC. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 119: 2550-2563, 2009.
22. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 181: 254-263, 2010.